Iqvia (NYSE:IQV) Price Target Raised to $181.00 at Robert W. Baird
Iqvia (NYSE:IQV) had its target price lifted by Robert W. Baird from $172.00 to $181.00 in a research note released on Thursday morning, BenzingaRatingsTable reports. They currently have an outperform rating on the medical research company’s stock.
IQV has been the topic of a number of other research reports. ValuEngine downgraded shares of Iqvia from a hold rating to a sell rating in a research report on Tuesday, February 4th. Stifel Nicolaus boosted their price target on shares of Iqvia from to and gave the stock a buy rating in a research report on Wednesday. Credit Suisse Group restated a buy rating and issued a $170.00 price target on shares of Iqvia in a research report on Friday, December 20th. Citigroup boosted their price target on shares of Iqvia from $185.00 to $195.00 and gave the stock a buy rating in a research report on Thursday. Finally, Cfra upgraded shares of Iqvia from a hold rating to a buy rating and boosted their price target for the stock from $148.00 to $185.00 in a research report on Wednesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seventeen have given a buy rating to the company. Iqvia currently has a consensus rating of Buy and a consensus price target of $174.30.
Shares of NYSE IQV traded down $1.47 during midday trading on Thursday, reaching $164.32. The stock had a trading volume of 2,962,308 shares, compared to its average volume of 1,312,776. The firm has a market cap of $31.03 billion, a price-to-earnings ratio of 134.69, a price-to-earnings-growth ratio of 1.70 and a beta of 0.91. Iqvia has a twelve month low of $130.77 and a twelve month high of $169.14. The company has a debt-to-equity ratio of 1.85, a quick ratio of 1.12 and a current ratio of 1.12. The company’s 50 day moving average price is $158.20 and its 200 day moving average price is $151.72.
In related news, Director Michael J. Evanisko sold 6,250 shares of the business’s stock in a transaction on Friday, January 17th. The shares were sold at an average price of $160.76, for a total transaction of $1,004,750.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Michael R. Mcdonnell sold 12,000 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $155.07, for a total transaction of $1,860,840.00. Following the transaction, the chief financial officer now owns 14,366 shares in the company, valued at approximately $2,227,735.62. The disclosure for this sale can be found here. Insiders have sold a total of 37,000 shares of company stock worth $5,830,215 in the last quarter. 6.00% of the stock is owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its stake in Iqvia by 9.3% during the 2nd quarter. BlackRock Inc. now owns 13,436,830 shares of the medical research company’s stock valued at $2,161,986,000 after purchasing an additional 1,146,138 shares in the last quarter. Valeo Financial Advisors LLC increased its stake in Iqvia by 8.8% during the 3rd quarter. Valeo Financial Advisors LLC now owns 2,230 shares of the medical research company’s stock valued at $333,000 after purchasing an additional 180 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in Iqvia by 27.1% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 24,842 shares of the medical research company’s stock valued at $3,710,000 after purchasing an additional 5,294 shares in the last quarter. Massey Quick Simon & CO. LLC bought a new stake in Iqvia during the 3rd quarter valued at $43,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in Iqvia during the 3rd quarter valued at $215,000. Institutional investors own 89.93% of the company’s stock.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.